Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robin Smith

Neurology with Special Qualifications in Child Neurology Garden City, NY Medical Doctor

NPI 1518037647 CMS profile 67837

990 Stewart Ave, Suite 400, Garden City, NY 11530

Open in the dashboard

General payments

$7,728

392 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robin Smith of Garden City, NY is reported in the CMS Open Payments database as having received $7,728 across 392 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $927 44
2024 General $1,163 58
2023 General $849 44
2022 General $1,319 65
2021 General $1,345 63
2020 General $925 60
2019 General $1,200 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robin Smith
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Robin Smith were reported at $927. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Robin Smith Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $1,200 $262 $68–$1,313 $163
2020 $925 $188 $46–$1,222 $114
2021 $1,345 $183 $45–$1,356 $132
2022 $1,319 $229 $72–$1,177 $149
2023 $849 $269 $93–$1,195 $160
2024 $1,163 $300 $98–$1,428 $164
2025 $927 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $1,036 47 payments
  2. Tris Pharma Inc $914 61 payments
  3. Corium, Inc. $880 53 payments
  4. Ironshore Pharmaceuticals Inc. $812 47 payments
  5. UCB, Inc. $716 30 payments
  6. Eisai Inc. $522 19 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $487 19 payments
  8. Neurelis, Inc. $465 20 payments
  9. Greenwich Biosciences, Inc. $307 13 payments
  10. Adlon Therapeutics L.P. $242 13 payments
  11. Other $1,347 70 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,728 392 payments
Products named General payments · program years 2019–2025
  1. Azstarys $880 53 payments
  2. QELBREE $669 27 payments
  3. JORNAY PM $597 34 payments
  4. Briviact $552 23 payments
  5. Fycompa $522 19 payments
  6. VALTOCO $465 20 payments
  7. Dyanavel XR $462 29 payments
  8. VYVANSE $443 17 payments
  9. Epidiolex $392 16 payments
  10. ADHANSIA XR $242 13 payments
  11. Other $2,661 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

392 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record